同病性结性脊柱炎和全身性红斑狼:一个治疗挑战
Charles E DeBoisblanc1, Victor E Nava2, Suman Chauhan3
1Internal Medicine, George Washington University, Washington, DC, USA.
Cureus
|April 29, 2024
概括
脊髓缩性脊髓炎 (AS) 和全身性红斑狼 (SLE) 是罕见的类风湿病,可以同时发生. 本案例报告强调了管理AS和SLE并发症的诊断和治疗挑战.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 内部医学 内部医学
背景情况:
- 脊髓缩性脊髓炎 (AS) 和全身性红斑狼 (SLE) 是不同的自身免疫疾病,影响多个器官系统.
- 单个患者中AS和SLE的同时出现是非常罕见的,记录的病例有限.
- 管理患有AS和SLE的患者具有独特的临床复杂性.
研究的目的:
- 报告一种罕见的并发性结性脊髓炎和全身性红斑狼病例.
- 讨论在同时识别两种疾病时遇到的诊断困难.
- 探索AS和SLE同时存在的患者的潜在治疗策略.
主要方法:
- 一个被诊断患有结性脊髓炎和全身性红斑狼的患者的案例介绍.
- 对AS和SLE的诊断标准和临床表现的审查.
- 讨论治疗选择,考虑潜在的药物相互作用和重叠的症状.
主要成果:
- 该案例说明了区分AS和SLE之间重叠症状的挑战.
- 由于并发症表现的罕见性和复杂性,诊断可能会出现延迟.
- 治疗决策需要仔细考虑免疫抑制和抗炎治疗.
结论:
- 同病性AS和SLE在风湿病学中构成了诊断和治疗方面的挑战.
- 早期识别和综合管理对于最佳的患者结果至关重要.
- 需要进一步研究AS和SLE共存的病原和最佳治疗方法.
相关概念视频
Autoimmune Disorders
417
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
417
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
160
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
160
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
Chronic Bowel Disorders: Introduction
446
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
446
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
134
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
134


